Conventional DAPT is named as an intervention in 2 current clinical trials in our China and Switzerland registers. 2 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Zunyi Medical College (1). The most-studied condition is ACS - Acute Coronary Syndrome.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention
NCT06283888 · ClinicalTrials.gov ↗ · ACS - Acute Coronary Syndrome, CYP2C19 Polymorphism
|
Phase 4 | Recruiting | Zunyi Medical College | China |
|
Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)
NCT05650411 · ClinicalTrials.gov ↗ · Left Main Coronary Artery Stenosis
|
Not applicable | Recruiting | IGLESIAS Juan Fernando | Switzerland |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Zunyi Medical College | 1 |
| IGLESIAS Juan Fernando | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 1 |
| Clinical trials in Switzerland | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China and Switzerland registers name Conventional DAPT as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 1 with sites in China and 1 with sites in Switzerland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Zunyi Medical College (1) and IGLESIAS Juan Fernando (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Conventional DAPT works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Conventional DAPT works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Conventional DAPT (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.